Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Receivables - Accured (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Receivables - Accured for 5 consecutive years, with $6.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables - Accured rose 18.52% to $6.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.4 million, a 18.52% increase, with the full-year FY2025 number at $6.4 million, up 18.52% from a year prior.
  • Receivables - Accured was $6.4 million for Q4 2025 at Janux Therapeutics, up from $6.3 million in the prior quarter.
  • In the past five years, Receivables - Accured ranged from a high of $28.0 million in Q3 2021 to a low of $3000.0 in Q2 2021.
  • A 5-year average of $4.1 million and a median of $2.2 million in 2023 define the central range for Receivables - Accured.
  • Biggest YoY gain for Receivables - Accured was 9900.0% in 2022; the steepest drop was 98.93% in 2022.
  • Janux Therapeutics' Receivables - Accured stood at $200000.0 in 2021, then skyrocketed by 250.0% to $700000.0 in 2022, then soared by 214.29% to $2.2 million in 2023, then soared by 145.45% to $5.4 million in 2024, then rose by 18.52% to $6.4 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Receivables - Accured are $6.4 million (Q4 2025), $6.3 million (Q3 2025), and $5.7 million (Q2 2025).